基于CRISPR/Cas12a的HIV-1 C亚型婴儿快速检测方法
该研究开发了一种基于CRISPR/Cas12a的HIV-1 C亚型检测方法,通过RPA等温预扩增结合crRNA靶向pol基因保守区,利用荧光、视觉读数和侧流试纸条实现快速可视化检测。在41例HIV-1C血清阳性个体(含28例感染婴儿)及31例健康 donor 血浆中评估,灵敏度96%、特异性92.65%,有望作为2岁以下婴儿母婴传播的快速核酸检测替代方案。
要点
- CRISPR/Cas12a联合RPA的HIV-1C检测方法灵敏度96%、特异性92.65%。
- 该方法兼容荧光、视觉读数和侧流试纸条三种读取方式。
- 适用于2岁以下婴儿,弥补母体抗体干扰导致血清学检测无效的不足。
核心结论
- 基于CRISPR/Cas12a的HIV-1C检测方法对C亚型具有高灵敏度和特异性,有望作为床旁分子诊断工具。
- 该方法可作为2岁以下婴儿HIV-1C母婴传播的快速核酸检测替代方案,弥补传统抗体检测无效的缺陷。
研究设计与样本
- 研究开发了靶向HIV-1 pol基因保守区的CRISPR/Cas12a检测方法,采用RPA等温预扩增。
- 性能评估使用41例HIV-1C血清阳性个体血浆(含28例感染婴儿)、HIV-1印度C亚型和B亚型基因组质粒、病毒性疾病对照DNA/RNA样本(流感、RSV、细小病毒、HPIV、CMV、HBV)及31例健康 donor 血浆。
主要发现
- 该检测方法灵敏度为96%,特异性为92.65%。
- 检测结果可通过荧光和视觉读数获得,并兼容侧流试纸条格式。
关键数值与推荐
- 灵敏度96%,特异性92.65%,基于41例HIV-1C血清阳性个体(含28例感染婴儿)和31例健康 donor 血浆的评估。
临床怎么用
- 可用于HIV-1C的快速床旁分子检测,尤其适用于2岁以下婴儿的早期诊断。
- 检测结果可通过荧光、视觉或侧流试纸条读取,便于在资源有限场景中应用。
局限性
- 评估样本量有限,仅针对HIV-1 C亚型,未报告其他亚型的交叉反应数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early detection of HIV-1 infection is essential for initiating antiretroviral therapy (ART) to suppress viremia and prevent disease progression. Timely diagnosis, especially in infants, is critical as rapid antibody-based serology tests are ineffective due to the presence of maternal antibodies. METHODS: We developed a CRISPR/Cas12a-based HIV-1 detection assay by optimizing components for coupled isothermal preamplification using recombinase polymerase amplification (RPA). The assay targeted the conserved region in the pol gene specific to HIV-1 with the designed CRISPR RNA (crRNA). CRISPR/Cas12a-mediated cleavage of viral cDNA was visualized through the collateral cleavage of a single-stranded DNA-FAM-BQ reporter, enabling rapid and visually detectable outcomes. The performance of the assay was evaluated using plasma from 41 HIV-1 Clade C (HIV-1C) seropositive individuals, including 28 HIV-1C infected infant samples, HIV-1 Indian Clade C and Clade B genome plasmids, viral disease control DNA/RNA samples (Influenza, RSV, Parvovirus, HPIV, CMV, and HBV), and 31 healthy donor plasma samples. Sensitivity and specificity were assessed, and detection was performed using fluorescence, visual readout, and lateral flow dipsticks. RESULTS: The CRISPR/Cas12a-based HIV-1 Clade C detection assay achieved a sensitivity of 96 % and a specificity of 92.65 %. The assay successfully provided results through both fluorescence and visual readouts and was compatible with lateral flow dipstick formats, facilitating easy and rapid detection. CONCLUSIONS: The developed CRISPR/Cas12a-based HIV-1C detection assay demonstrates high sensitivity and specificity for Clade C, indicating its potential as a robust point-of-care molecular diagnostic tool for HIV-1C. Additionally, it may serve as a rapid nucleic acid test alternative for detecting mother-to-child transmission of HIV-1C in infants under two years of age, where traditional antibody-based tests are ineffective. This assay holds promise for improving early HIV-1 diagnosis and timely initiation of ART, ultimately contributing to better disease management and outcomes.
引用
- Gaur A, Bhakhri H, Mishra N, et al. A rapid CRISPR/Cas12a-based assay for the detection of HIV-1 Clade C in infants. Clin Chim Acta. 2025. PMID: 40749819. doi:10.1016/j.cca.2025.120518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。